Currently Enrolling Trials
Syfovre (pegcetacoplan) injection is a complement inhibitor.
Syfovre is specifically indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Syfovre is supplied as an injection for intravenous administration. The recommended dose is 15 mg (0.1 mL of 150 mg/mL solution) administered by intravitreal injection to each affected eye once every 25 to 60 days.
Mechanism of Action
Pegcetacoplan binds to complement protein C3 and its activation fragment C3b with high affinity thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation.
Adverse effects associated with the use of Syfovre may include, but are not limited to, the following:
- ocular discomfort
- neovascular age-related macular degeneration
- vitreous floaters
- conjunctival hemorrhage
Clinical Trial Results
The FDA approval of Syfovre was based on results from the Phase 3 OAKS and DERBY studies at 24 months.